http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2085171-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-3873
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
filingDate 1992-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be086adb1ab72baa7e06e06724c6a284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a503963ba7fa150ee5cd46f169bcb65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57a3be057e3880135540e84a15ba1753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d263d26c8b2627e6658ab5d5df7c8a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f89c25a44bac6368b4407755122626f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ace28301d60db270dc7c86f539552f1c
publicationDate 1993-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2085171-A1
titleOfInvention Guanidinoalkyl-1, 1-bisphosphonic acid derivatives, process for their preparation and their use
abstract Guanidinoalkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use The invention describes tautomeric compounds of the formula Ia, Ib or Ic (see Formula Ia, Ib) (see Formula Ic) and/or their physiologically tolerable salts, in which R1, R2, R3, R4, R5, R6 and R7 are a hydrogen atom, substituted (C1-C7)-alkyl, (C3-C10)-cycloalkyl, substituted phenyl or (C1-C4)-alkylphenyl, R2 is substituted phosphoric acid, R2 and R3, R2 and R5 or R4 and R5 form a monocyclic 5- to 7-membered saturated or unsaturated heterocyclic ring which is mono- or polysubstituted, R8, R9, R10 and R11 are a hydrogen atom or (C1-C5)-alkyl, X is a hydrogen atom, hydroxyl or halogen, 1 and n are an integer from 0 to 7, m is an integer from 0 to 2, and the sum of the numbers l, m and n is less than or equal to 10, a process for the preparation of the compounds of the formula Ia, Ib or Ic, pharmaceuticals and their use for the prophylaxis or treatment of osteoporosis.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5498617-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5661174-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5395826-A
priorityDate 1991-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550722
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310

Total number of triples: 35.